BioStock: Promore Pharma’s phase II study running according to plan

Solna-based pharmaceutical company Promore Pharma focuses on therapeutic peptides in wound care and scarring, two areas where there currently is a lack of pharmaceutical products. The lead project ensereptide is indicated for prevention of scarring, and the company is currently conducting a phase IIa study with the candidate. BioStock has taken a closer look at the ongoing study and its importance to the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/promore-pharmas-phase-ii-study-running-according-to-plan/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se